Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Cash from Investing Activities: 2009-2025

Historic Cash from Investing Activities for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to -$35.2 million.

  • BIO-TECHNE's Cash from Investing Activities rose 102.79% to $605,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 81.74%. This contributed to the annual value of -$35.2 million for FY2025, which is 82.67% up from last year.
  • As of FY2025, BIO-TECHNE's Cash from Investing Activities stood at -$35.2 million, which was up 82.67% from -$203.0 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Cash from Investing Activities registered a high of -$35.2 million during FY2025, and its lowest value of -$265.6 million during FY2023.
  • In the last 3 years, BIO-TECHNE's Cash from Investing Activities had a median value of -$203.0 million in 2024 and averaged -$168.0 million.
  • Per our database at Business Quant, BIO-TECHNE's Cash from Investing Activities tumbled by 998.75% in 2021 and then soared by 82.67% in 2025.
  • Yearly analysis of 5 years shows BIO-TECHNE's Cash from Investing Activities stood at -$243.5 million in 2021, then surged by 60.23% to -$96.9 million in 2022, then crashed by 174.29% to -$265.6 million in 2023, then rose by 23.57% to -$203.0 million in 2024, then spiked by 82.67% to -$35.2 million in 2025.